Author

Allison S. Limpert

Sanford Burnham Prebys Medical Discovery InstituteORCID 0009-0002-1384-5697Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1

Frequent Co-Authors

Douglas J. SheffleriD· 4 shared Fabiana Izidro LayngiD· 4 shared Nicholas D. P. CosfordiD· 4 shared Dhanya R. Panickar· 3 shared Lester J. LambertiD· 3 shared Maria Celeridad· 3 shared Reuben J. ShawiD· 3 shared Sonja N. Brun· 3 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Douglas J. ShefflerORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Reversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase

Joseph Fromm, Alexander Aleshin, Lester J. Lambert, Laurent J. S. De Backer, Santhi Reddy, Margrith E. Mattmann, Allison S. Limpert, Palak Gosalia, Carina D. Wimer, Fabiana Izidro Layng, Maria Celeridad, Robert Ardecky, Peter Teriete, David A. Scott, Michael P. Hedrick, , Nicholas D. P. Cosford

This paper reports the discovery of SBP-5917, a reversible FASN-TE inhibitor with submicromolar potency and cellular target engagement.

bioRxiv · Oct 7, 2026 · PreprintCell Biology

Synthesis and Characterization of ULK1/2 Kinase Inhibitors that Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer

Fabiana Izidro Layng, Huiyu Ren, Nicole A. Bakas, Dhanya R. Panickar, Lester J. Lambert, Maria Celeridad, Jiaqian Wu, Laurent J. S. De Backer, Preeti Chandrachud, Allison S. Limpert, Mitchell Vamos, A. Chaikuad, Betsaida Bibo‐Verdugo, Patrick M. Hagan, Sonja N. Brun, , Nicholas D. P. Cosford

The paper reports the design, synthesis, and characterization of new ULK1/2 inhibitors that inhibit autophagy and upregulate MHC I in NSCLC cells, supporting their potential as cancer therapeutics.

ACS Chemical Biology · Feb 12, 2026Peer-reviewedCancer Biology

ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers

Patrick M. Hagan, Huiyu Ren, Sonja N. Brun, Fabiana Izidro Layng, Dhanya R. Panickar, Lester J. Lambert, Maria Celeridad, Ranajit Das, Ling Li, Yijuan Zhang, Allison S. Limpert, Douglas J. Sheffler, Cosimo Commisso, Reuben J. Shaw, Nicholas D. P. Cosford

The paper identifies SBP-1750, a ULK inhibitor that degrades ATG13 and kills KRAS-mutant cancer cells, showing efficacy in vivo and immune enhancement.

bioRxiv · Oct 14, 2025 · PreprintCancer Biology

Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer

Suzanne Dufresne, Ramya S. Kuna, Kristiana Wong, Anvita Komarla, Louis R. Parham, Celina Shen, Payel Mondal, Adelaida Estrada-Cardenas, Angelica E. Rock, Joel Encarnación-Rosado, Amanda Cyril, Ginevra Doglioni, Dhanya R. Panickar, Nicole A. Bakas, Douglas J. Sheffler, , Christina G. Towers

This study identifies metabolic adaptations in pancreatic cancer cells resistant to autophagy inhibitors and shows that targeting pyrimidine salvage can enhance treatment efficacy.

bioRxiv · May 29, 2025 · PreprintCancer Biology